Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Veracyte Inc (NASDAQ: VCYT) closed the day trading at $29.95 up 4.68% from the previous closing price of $28.61. In other words, the price has increased by $4.68 from its previous closing price. On the day, 0.97 million shares were traded. VCYT stock price reached its highest trading level at $29.96 during the session, while it also had its lowest trading level at $28.55.
Ratios:
For a better understanding of VCYT, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.06. For the most recent quarter (mrq), Quick Ratio is recorded 5.10 and its Current Ratio is at 5.43. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on March 20, 2025, initiated with a Buy rating and assigned the stock a target price of $45.
On December 05, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $38 to $37.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $50.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’25 when EASTHAM KARIN sold 4,590 shares for $26.66 per share. The transaction valued at 122,388 led to the insider holds 13,907 shares of the business.
Bhanji Muna sold 4,589 shares of VCYT for $122,367 on Jun 13 ’25. The Director now owns 29,989 shares after completing the transaction at $26.67 per share. On Jun 13 ’25, another insider, KARIN EASTHAM, who serves as the Director of the company, bought 4,590 shares for $26.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 2356214528 and an Enterprise Value of 1980721152. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 90.02, and their Forward P/E ratio for the next fiscal year is 20.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.92 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 4.134 whereas that against EBITDA is 31.056.
Stock Price History:
The Beta on a monthly basis for VCYT is 2.07, which has changed by -0.05071318 over the last 52 weeks, in comparison to a change of 0.15109766 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $47.32, while it has fallen to a 52-week low of $22.61. The 50-Day Moving Average of the stock is 11.82%, while the 200-Day Moving Average is calculated to be -10.34%.
Shares Statistics:
Over the past 3-months, VCYT traded about 1.44M shares per day on average, while over the past 10 days, VCYT traded about 953490 shares per day. A total of 78.60M shares are outstanding, with a floating share count of 76.87M. Insiders hold about 2.29% of the company’s shares, while institutions hold 106.62% stake in the company. Shares short for VCYT as of 1755216000 were 8157909 with a Short Ratio of 5.68, compared to 1752537600 on 6111924. Therefore, it implies a Short% of Shares Outstanding of 8157909 and a Short% of Float of 11.57.
Earnings Estimates
The stock of Veracyte Inc (VCYT) is currently drawing attention from 9.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.37, with high estimates of $0.4 and low estimates of $0.35.
Analysts are recommending an EPS of between $1.47 and $1.38 for the fiscal current year, implying an average EPS of $1.43. EPS for the following year is $1.43, with 9.0 analysts recommending between $1.92 and $1.13.
Revenue Estimates
9 analysts predict $124.62M in revenue for the current quarter. It ranges from a high estimate of $125.97M to a low estimate of $123.9M. As of the current estimate, Veracyte Inc’s year-ago sales were $115.86MFor the next quarter, 9 analysts are estimating revenue of $131.01M. There is a high estimate of $132.8M for the next quarter, whereas the lowest estimate is $128.8M.
A total of 10 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $502.81M, while the lowest revenue estimate was $497.4M, resulting in an average revenue estimate of $500.29M. In the same quarter a year ago, actual revenue was $445.76MBased on 10 analysts’ estimates, the company’s revenue will be $549.29M in the next fiscal year. The high estimate is $560M and the low estimate is $540.64M.
